9. Sep. 2019OA Dr. Maximilian Hochmair
WCLC 2019: Zusätzliche Immuntherapie beim Kleinzeller ist Standard
Für OA Dr. Maximilian Hochmair, Leiter der pneumo-onkologischen Ambulanz und Tagesklinik, Krankenhaus Nord, Wien, brachte die World Conference on Lung Cancer viele neue Puzzlesteine, darunter Durvalumab als weitere Option beim kleinzelligen Lungenkarzinom.
Inhalte im Video:
Interview mit:
Produziert von:
Abstracts, die im Video diskutiert werden:
- PL02.02 – Lung Cancer Screenee Selection by USPSTF Versus PLCOm2012 Criteria – Interim ILST Findings
Stephen Lam - PL02.04 – Blood MicroRNA and LDCT Reduce Unnecessary LDCT Repeats in Lung Cancer Screening: Results of Prospective BioMILD Trial
Ugo Pastorino - PL02.06 – In Hospital Clinical Efficacy, Safety and Oncologic Outcomes from VIOLET: A UK Multi-Centre RCT of VATS Versus Open Lobectomy for Lung Cancer
Eric Lim - PL02.11 – Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study
Luis Paz-Ares - OA14.06 – Hyperprogressive Disease in Advanced Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
Lo Russo Guiseppe - P1.01-118 Overall Survival In Pts With Egfrm+ Nsclc Receiving Sequential Afatinib And Osimertinib: Updated Analysis Of The GIOTAG Study
M.J. Hochmair
Quelle
2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer, Barcelona, 7.-10.9.19